GEn1E is a clinical-stage multi-target AI platform. They develop novel, next-gen, immunomodulators for rare &a; inflammatory diseases.
Business Model:
Revenue: $0
Employees: 11-50
Address:
City: Palo Alto
State: California
Zip:
Country: United States
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare &a; inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 8/2019 | Seed Round | 3 | - |
Khosla Ventures Milad Alucozai Y Combinator Khosla Ventures Milad Alucozai Y Combinator |
8/2021 | Seed Round | 1 | - |
10X Capital 10X Capital |
1/2021 | Seed Round | 3 | - |
10X Capital Bossanova Investimentos Stanford Angels and Entrepreneurs 10X Capital Bossanova Investimentos Stanford Angels and Entrepreneurs |
2/2020 | Seed Round | 1 | - |
Neue Fund Harmonix Fund Neue Fund Harmonix Fund |
12/2022 | Venture Round | $17M | 8/2021 | Seed Round | 1 | - |
10X Capital 10X Capital |
1/2021 | Seed Round | 3 | - |
10X Capital Bossanova Investimentos Stanford Angels and Entrepreneurs 10X Capital Bossanova Investimentos Stanford Angels and Entrepreneurs |
2/2020 | Seed Round | 1 | - |
Neue Fund Neue Fund |
8/2019 | Seed Round | 3 | - |
Khosla Ventures Milad Alucozai Y Combinator Khosla Ventures Milad Alucozai Y Combinator |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|